IPHA News

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today reported its financial update for the nine months ended September 30, 2026. As we approach year-end, our strengthened cash position enables us to work towards executing the next steps in advancing...

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced that AstraZeneca has updated the expected timing for the PACIFIC-9 Phase 3 trial high-level data readout to the first half of 2027, from the second half of 2026 previously. The revised...

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced that members of its executive team will participate in the following investor conferences: Stifel...

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announces that the Company will hold a conference call on Thursday, November 5, 2026, at 2 p.m. CET / 8 a.m. ET, to provide a business and financial update for the third quarter of 2026. Participants...

Innate Pharma (IPHA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Innate Pharma (IPHA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Innate Pharma (IPHA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today reported its consolidated financial results for the six months ended June 30, 2026. The consolidated financial statements are attached to this press release. 2026 continues to be an important year of...